Choi Jae Hwi, Hwa Jung Seog, Kam Sung Chul, Jeh Seong Uk, Hyun Jae Seog
Department of Urology, Gyeongsang National University School of Medicine, Jinju, Korea.
World J Mens Health. 2014 Aug;32(2):99-104. doi: 10.5534/wjmh.2014.32.2.99. Epub 2014 Aug 26.
Previous studies have revealed that tamsulosin is effective in improving lower urinary tract symptoms (LUTS) and erectile functioning but has some inhibitory effects on ejaculation, including decreased ejaculatory volume. However, these inhibitory effects on ejaculation can be beneficial to patients with premature ejaculation (PE). Therefore, this study was conducted to understand the effect of tamsulosin on PE in men with benign prostatic hyperplasia.
Twenty-nine patients who visited with LUTS were categorized into 2 groups of LUTS-only patients (n=12) and LUTS combined with PE (LUTS+PE) patients (n=17), and 0.4 mg of tamsulosin was administered to the patients of both groups for 12 weeks. Comparative analyses of before and after the treatment were conducted for calculating the International Prostate Symptom Score (IPSS), International Index of Erectile Function-5 (IIEF-5), intravaginal ejaculatory latency time (IELT), premature ejaculation diagnostic tool (PEDT), and premature ejaculation profile (PEP). The patients with an IPSS score of 8 or higher were determined as LUTS patients, and the patients with IELT of less than 2 minutess and a PEDT score of 9 or higher were determined as PE patients.
After treatment, the IPSS score significantly decreased in both groups. There was no statistically significant change in the PEDT for the LUTS group, but there was a significant decrease in PEDT (p=0.012; from 12.1±3.31 to 8.4±4.49) in the LUTS+PE group.
Tamsulosin not only has a treatment effect for LUTS but also improves the PE of LUTS+PE patients. Therefore, further studies are needed to confirm the effects of tamsulosin on PE.
既往研究表明,坦索罗辛可有效改善下尿路症状(LUTS)及勃起功能,但对射精有一定抑制作用,包括射精量减少。然而,这些对射精的抑制作用对早泄(PE)患者可能有益。因此,本研究旨在了解坦索罗辛对良性前列腺增生男性患者早泄的影响。
29例因LUTS就诊的患者分为单纯LUTS组(n = 12)和LUTS合并PE(LUTS+PE)组(n = 17),两组患者均给予0.4 mg坦索罗辛治疗12周。对治疗前后进行比较分析,计算国际前列腺症状评分(IPSS)、国际勃起功能指数-5(IIEF-5)、阴道内射精潜伏期(IELT)、早泄诊断工具(PEDT)和早泄概况(PEP)。IPSS评分≥8分的患者被判定为LUTS患者,IELT<2分钟且PEDT评分≥9分的患者被判定为PE患者。
治疗后,两组患者的IPSS评分均显著降低。LUTS组的PEDT无统计学显著变化,但LUTS+PE组的PEDT显著降低(p = 0.012;从12.1±3.31降至8.4±4.49)。
坦索罗辛不仅对LUTS有治疗作用,还可改善LUTS+PE患者的早泄症状。因此,需要进一步研究以证实坦索罗辛对早泄的影响。